The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Transdermal GFR System (TGFR) is a first-in-kind product ... More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with ...

The Creve Coeur-based company is developing the use of proprietary fluorescent tracer agents as a noninvasive way to test ...

Children with AAV and kidney disease face increased risks for long-term renal damage at 1 year, despite the majority achieving inactive renal disease by this time.

Annual health checkups regularly include urine tests that serve several purposes, including checking for symptoms of kidney ...

Many older people develop chronic kidney disease and are also likely to be on cholesterol-lowering drugs known as statins.

MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the ...

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of Iowa has found.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Statins, which are prescription drugs that can reduce cholesterol levels and lower the risk for heart disease, don’t affect kidney function, new research shows.

A University of Iowa research team has found that a class of cholesterol-lowering drugs have no effect on kidney function.